Biosynth offers MOSCERDAM fluorogenic substrates for lysosomal storage disorders with 10x higher sensitivity than traditional methods.
Public source
Publisher name
Public post
Lysosomal storage disorders (LSDs) demand precision, and MOSCERDAM™ substrates deliver. These fluorogenic substrates enable highly sensitive detection of lysosomal enzym…
Company
Biosynth
Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Location
- Staad, CH
- Company size
- 201–500 employees
About Biosynth
Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals. Where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. Biosynth's mission is to supply critical raw materials and services to the pharmaceutical and diagnostic industries. Biosynth strives to de-risk its customer's supply chains. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Biosynth is a life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in complex chemistry, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than a million products in our research catalog and hundreds of complex manufacturing service projects. The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. Biosynth's services and products include enzyme development and biocatalysis, reagents for in vitro diagnostics and bioconjugation chemistry. Biosynth is owned, among others by KKR, Ampersand and Senior Management.
See moreLatest activity
Latest activity from Biosynth
4 signals
Presence & Recognition
Biosynth partners are building breakthroughs at CPhI.
Operations & Supply
Biosynth integrated end-to-end peptide capabilities at the Netherlands site to support teams from early discovery to clinical supply.
Presence & Recognition
Biosynth is attending the CPHI Milan conference in Booth 10M62 to discuss the next evolution of the Glyco Toolbox.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
Syngene International Limited
Syngene International Limited rethought an orphan drug API route through process intensification, simplified synthesis, cut reliance on chromatography and palladium, and introduced safer reagents to achieve a scalable, cost-efficient process.
Products & Services
Enamine Ltd.
Enamine Ltd. launched the Enamine Fast MADE Building Block Catalog on EnamineStore.com, featuring 100 million molecules, 85% of orders synthesized in less than 10 working days, and 98% completed orders.
Products & Services
Curapath
Curapath added a new product page for Poly-L-Arginine and Polypeptoids to its Polyamino Acids and Polypeptoids section.
Products & Services
Eurofins CDMO Europe
Eurofins CDMO Europe showcased its new global website designed to easily access information, expertise, and services across the global network.
Products & Services
BOC Sciences